Creatine cerebral deficiency syndrome 3 (CCDS3), also known as arginine:glycine amidinotransferase (AGAT) deficiency, is an autosomal recessive inherited metabolic disorder caused by variants in the GATM gene. The alteration reduces the endogenous synthesis of creatine, a molecule essential for the rapid supply of energy in the brain and muscle.
Cerebral creatine deficiency syndrome 3 (GATM)
The GATM gene encodes the enzyme arginine:glycine amidinotransferase, also known as AGAT. This enzyme catalyzes the first step of creatine biosynthesis, mainly in the kidney and pancreas, by transferring an amidino group from arginine to glycine to form guanidinoacetate and ornithine. Subsequently, guanidinoacetate is converted to creatine by the action of the GAMT enzyme. Creatine acts as a rapid energy reserve in tissues with high demand, especially the brain and muscle. When biallelic pathogenic variants exist in GATM, AGAT activity decreases or is lost, blocking the production of guanidinoacetate and, consequently, creatine synthesis. The result is a systemic creatine deficiency with significant involvement of the central nervous system, where the lack of energy availability contributes to developmental delay and other neurological symptoms. Unlike GAMT deficiency, no toxic accumulation of guanidinoacetate occurs. Inheritance is autosomal recessive and the disease is ultrarare, with very few cases described in the medical literature. No clear ethnic or geographic predilection has been established.
Symptoms
The onset of CCDS3 usually occurs in infancy, although severity can vary. Main symptoms include global developmental delay, mild to moderate intellectual disability, significant speech and language delay, hypotonia, and muscle weakness. Seizures, movement disorders, hyperactivity, or autism spectrum features have been described in some patients. The outcome can improve significantly if treatment is initiated early.
Disease management
The management of CCDS3 is based on oral creatine supplementation, which can replenish brain levels because the creatine transporter is conserved. The response is generally better than in SLC6A8 transporter deficiency, especially when treatment begins before established neurological damage. Dietary restrictions of arginine or ornithine supplementation are usually not required, unlike in GAMT deficiency. Management is completed with seizure control, neurological monitoring, and rehabilitative, educational, and speech support.
Genes analyzed
Bibliography
Goldstein J, Thomas-Wilson A, Groopman E, et al. ClinGen variant curation expert panel recommendations for classification of variants in GAMT, GATM and SLC6A8 for cerebral creatine deficiency syndromes. Mol Genet Metab. 2024 May;142(1):108362.
Mulik C, Mercimek-Andrews S. Creatine Deficiency Disorders: Phenotypes, Genotypes, Diagnosis, and Treatment Outcomes. Turk Arch Pediatr. 2023 Mar;58(2):129-135.
Hanna-El-Daher L, Braissant O. Creatine synthesis and exchanges between brain cells: What can be learned from human creatine deficiencies and various experimental models? Amino Acids. 2016 Aug;48(8):1877-95.
